SHANDONG NEW TIME PHARMACEUTICAL CO LTD
PharmaSHANDONG NEW TIME PHARMACEUTICAL CO LTD is a pharmaceutical company focused on Oncology, Neurology, Metabolic.
SHANDONG NEW TIME PHARMACEUTICAL CO LTD at a Glance
- Growing R&D activity with 8 trials in last 2 years
- Fast trial execution (25 months median completion)
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's Key Drugs
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's Recent FDA Approvals
New NDA/BLA approvals for SHANDONG NEW TIME PHARMACEUTICAL CO LTD over the last two years — novel drugs only, excluding generics and label supplements.
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's Therapeutic Areas
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's Top Competitors
SHANDONG NEW TIME PHARMACEUTICAL CO LTD's closest competitors by therapeutic-area and drug-target overlap include Takeda, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SHANDONG NEW TIME PHARMACEUTICAL CO LTD Pipeline Snapshot
SHANDONG NEW TIME PHARMACEUTICAL CO LTD has 11 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 6 Phase 2 and 2 Phase 1.
Phase 3 Readout Calendar Pro
3 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/3 completed
- • Speed: 25 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges